Jane Street’s BRAINSTORM CELL THERAPUTC BCLI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q3
Sell
-1,322
Closed -$6.71K 9568
2024
Q2
$6.71K Buy
1,322
+73
+6% +$547 ﹤0.01% 9141
2024
Q1
$10.6K Buy
+1,249
New +$6.87K ﹤0.01% 8962
2023
Q4
Sell
-2,038
Closed -$6.12K 9178
2023
Q3
$6.12K Buy
+2,038
New +$46.3K ﹤0.01% 8431
2023
Q1
Sell
-937
Closed -$23K 9021
2022
Q4
$23K Buy
+937
New +$35K ﹤0.01% 8578
2022
Q3
Sell
-806
Closed -$33K 9691
2022
Q2
$33K Buy
+806
New +$36.3K ﹤0.01% 9020
2021
Q3
Sell
-836
Closed -$44K 9913
2021
Q2
$48K Buy
+836
New +$44.7K ﹤0.01% 9518
2021
Q1
Sell
-2,549
Closed -$193K 9079
2020
Q4
$173K Buy
+2,549
New +$347K ﹤0.01% 7017
2020
Q3
Sell
-964
Closed -$197K 7144
2020
Q2
$162K Sell
964
-275
-22% -$29.6K ﹤0.01% 6496
2020
Q1
$86K Buy
+1,239
New +$96.7K ﹤0.01% 4981

Other funds holding BCLI

Jane Street's BCLI Position: Q3 2024 in Review

Jane Street sold out of BRAINSTORM CELL THERAPUTC (BCLI) in Q3 2024, closing a stake of 1,322 shares — an estimated $6.71K sold.

Jane Street first reported a position in BCLI in Q1 2020 and held it in 9 quarters. The position peaked at $173K in Q4 2020. 38 funds tracked by Wall St. Rank hold BCLI as of Q3 2024.

  • Jane Street reported no remaining BRAINSTORM CELL THERAPUTC position as of Q3 2024 after selling out during the quarter.
  • Jane Street sold 1,322 BRAINSTORM CELL THERAPUTC shares in Q3 2024, an estimated $6.71K.
  • Jane Street first reported a position in BRAINSTORM CELL THERAPUTC in Q1 2020 and held it in 9 quarters.
  • Jane Street's BRAINSTORM CELL THERAPUTC position peaked at $173K in Q4 2020.
  • 38 funds tracked by Wall St. Rank held BRAINSTORM CELL THERAPUTC as of Q3 2024.

Based on Jane Street's 13F filing for Q3 2024, filed 15 Nov 2024.